Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and "bridge" to autologous hematopoietic stem cell transplantation for relapsed/refractory hodgkin lymphoma

Click to increase image sizeClick to decrease image size AcknowledgmentThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Disclosure statementNo potential conflict of interest was reported by the author(s).Author contributionsPK: responsible for study design, extracting and analyzing data, interpreting results, updating reference lists and creating the summary of findings and writing the manuscript. MAZ: contributed to data collection, analyzing data and results and provided feedback on the manuscript. MAD: contributed to the design of the study, data analysis and results interpretation and provided feedback on the manuscript. MAB: contributed to data collection, analyzing data and results and provided feedback on the manuscript. AAG: evaluated all the tissue blocks and confirmed disease diagnosis and provided feedback on the manuscript. AAN: evaluated the imaging tests and assessed the disease burden prior and after chemotherapy and provided feedback on the manuscript. HAH: contributed to the design of the study, results interpretation and provided feedback on the manuscript. SK: contributed to the design of the study, and provided feedback on the manuscript.Data availability statementThe datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.